

REMARKS

In an Office Action dated July 31, 2008, claims 1 - 27 and 29 - 31 are pending; claims 1 - 27 are allowed; claim 29 is rejected; and claims 30 and 31 are objected to. Claims 29 and 31 have been cancelled from the present application. Claims 1 - 27 and 30 are currently pending.

Applicant acknowledges with appreciation the allowance of claims 1 - 27.

35 U.S.C. § 112, first paragraph

Claim 29 was rejected under 35 U.S.C. § 112, first paragraph as failing to comply with the written description requirement. Claim 29 has been cancelled from the present application. Therefore, the rejection is moot as to this claim.

Claim Objections

Claims 30 and 31 are objected to as being dependent upon a rejected base claim. Claim 30 has been amended to depend from claim 1, incorporating subject matter of claims 30 and 31. Claim 31 has been cancelled.


It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Dated: August 26, 2008

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988


Karen L. Prus

Attorney for Applicant
Reg. No. 39,337